These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33693561)

  • 41. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
    Tenorio AR; Zheng Y; Bosch RJ; Krishnan S; Rodriguez B; Hunt PW; Plants J; Seth A; Wilson CC; Deeks SG; Lederman MM; Landay AL
    J Infect Dis; 2014 Oct; 210(8):1248-59. PubMed ID: 24795473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
    J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.
    Jain V; Hartogensis W; Bacchetti P; Hunt PW; Hatano H; Sinclair E; Epling L; Lee TH; Busch MP; McCune JM; Pilcher CD; Hecht FM; Deeks SG
    J Infect Dis; 2013 Oct; 208(8):1202-11. PubMed ID: 23852127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
    Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
    J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India.
    Kausalya B; Saravanan S; Pallikkuth S; Pahwa R; Saini SR; Iqbal S; Solomon S; Murugavel KG; Poongulali S; Kumarasamy N; Pahwa S
    BMC Immunol; 2022 May; 23(1):24. PubMed ID: 35581554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
    Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
    Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.
    Spivak AM; Larragoite ET; Coletti ML; Macedo AB; Martins LJ; Bosque A; Planelles V
    Retrovirology; 2016 Dec; 13(1):88. PubMed ID: 27998278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation.
    Cheng D; Luo Z; Fu X; Stephenson S; Di Germanio C; Norris PJ; Fuchs D; Ndhlovu LC; Li QZ; Zetterberg H; Gisslen M; Price RW; Peng S; Jiang W
    Microbiol Spectr; 2022 Feb; 10(1):e0197521. PubMed ID: 34985329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.
    Gavegnano C; Haile WB; Hurwitz S; Tao S; Jiang Y; Schinazi RF; Tyor WR
    J Neuroinflammation; 2019 Sep; 16(1):182. PubMed ID: 31561750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.
    Chughlay MF; Barnes KI; El Gaaloul M; Abla N; Möhrle JJ; Griffin P; van Giersbergen P; Reuter SE; Schultz HB; Kress A; Tapley P; Webster RA; Wells T; McCarthy JS; Barber BE; Marquart L; Boyle MJ; Engwerda CR; Chalon S
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0158421. PubMed ID: 34694880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
    Mystakelis HA; Wilson E; Laidlaw E; Poole A; Krishnan S; Rupert A; Welker JL; Gorelick RJ; Lisco A; Manion M; Baker JV; Migueles SA; Sereti I
    AIDS; 2023 Oct; 37(12):1827-1835. PubMed ID: 37450602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.